Home/Filings/4/0001140361-25-026461
4//SEC Filing

Campbell Chad Thomas 4

Accession 0001140361-25-026461

CIK 0001275187other

Filed

Jul 17, 8:00 PM ET

Accepted

Jul 18, 6:06 PM ET

Size

14.2 KB

Accession

0001140361-25-026461

Insider Transaction Report

Form 4
Period: 2025-07-16
Campbell Chad Thomas
SVP/GM, Vascular Access
Transactions
  • Award

    Performance Right

    2025-07-16+26,26826,268 total
    Common Stock (26,268 underlying)
  • Award

    Common Stock

    2025-07-16+26,26894,076 total
Footnotes (2)
  • [F1]The acquisition of 26,268 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 26,268 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.
  • [F2]Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Issuer

ANGIODYNAMICS INC

CIK 0001275187

Entity typeother

Related Parties

1
  • filerCIK 0001706852

Filing Metadata

Form type
4
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 6:06 PM ET
Size
14.2 KB